This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second View: Discussing the rollout opportunities for Ascendis' YORVIPATH (palopegteriparatide), recently approved by the FDA for the treatment of hypoparathyroidism in adults
Ticker(s): ASNDWho's the expert?
Institution: Private Practice
- Private Practice Endocrinologist who is affiliated with the Albert Einstein College of Medicine
- Manages 25 patients with hypoparathyroidism
- Clinical and research interest in diabetes and hypoparathyroidism
Interview GoalThis call will discuss the current treatment landscape and the potential of YORVIPATH (palopegteriparatide), recently approved by the FDA for the treatment of hypoparathyroidism in adults along with its pre-approval data.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
